person · Reporting owner
Friedman David Matthew
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalyn Pharma Inc.AVLN · Entity 4662 | Director | April 29, 2026 | April 29, 2026 |
| Benitec Biopharma Inc.BNTC · Entity 5596 | Director | May 26, 2026 | May 29, 2026 |
| Veradermics, IncMANE · Entity 1907 | Director | February 03, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalyn Pharma Inc.
Report date April 29, 2026 · Filed April 29, 2026
This filing explicitly reported no securities owned.
Benitec Biopharma Inc.
Report date May 26, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.45 · Expires 2036-05-26 | Direct | 35,000 |
Reported balance
After 2026-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-26 · Grant · Acquired 35,000 · Balance 35,000 F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. F2: The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service.
F2: The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027.
Veradermics, Inc
Report date February 03, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03 | Direct | 43,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 43,000 · Balance 43,000 F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as an employee of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. F2: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as an employee of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service.
F2: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2026 Filed May 29, 2026 01:10 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0001193125-26-245918 · ownership.xml · derivative · entry 1 Friedman David Matthew · CIK 0002108980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-05-26 F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. F2 · derivative.exercise_date: The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005909 · wk-form4_1770336291.xml · derivative · entry 1 Friedman David Matthew · CIK 0002108980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2036-02-03 F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as an employee of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service. F2 · derivative.exercise_date: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.